Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
出版年份 2018 全文链接
标题
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
作者
关键词
-
出版物
CNS DRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-07-19
DOI
10.1007/s40263-018-0539-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor
- (2018) Annalaura Sabatucci et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans
- (2018) Patrick D. Skosnik et al. NEUROPHARMACOLOGY
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Familial abnormalities of endocannabinoid signaling in schizophrenia
- (2018) Dagmar Koethe et al. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial
- (2017) Ladan Kashani et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice
- (2017) A Busquets-Garcia et al. MOLECULAR PSYCHIATRY
- “Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York
- (2017) Axel J. Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pregnenolone does not interfere with the effects of cannabinoids on synaptic transmission in the cerebellum and the nucleus accumbens
- (2017) Anna Krohmer et al. PHARMACOLOGICAL RESEARCH
- Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
- (2016) Andreza B. Sonego et al. BEHAVIOURAL BRAIN RESEARCH
- Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
- (2016) Mohini Ranganathan et al. BIOLOGICAL PSYCHIATRY
- Therapeutic Potential of Cannabinoids in Psychosis
- (2016) F. Markus Leweke et al. BIOLOGICAL PSYCHIATRY
- Association Between Cannabis and Psychosis: Epidemiologic Evidence
- (2016) Suzanne H. Gage et al. BIOLOGICAL PSYCHIATRY
- An Introduction to the Endogenous Cannabinoid System
- (2016) Hui-Chen Lu et al. BIOLOGICAL PSYCHIATRY
- Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis
- (2016) Anahita Bassir Nia et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
- (2016) P Seeman Translational Psychiatry
- Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
- (2015) John M McPartland et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- (2015) Matthew W. Elmes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
- (2015) David D Aguilar et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Inflammation in schizophrenia: A question of balance
- (2015) Juan C. Leza et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Molecular Targets of Cannabidiol in Neurological Disorders
- (2015) Clementino Ibeas Bih et al. Neurotherapeutics
- Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
- (2014) Fabio Arturo Iannotti et al. ACS Chemical Neuroscience
- The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
- (2014) Thomas R. Insel AMERICAN JOURNAL OF PSYCHIATRY
- Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
- (2014) Marisol S. Castaneto et al. DRUG AND ALCOHOL DEPENDENCE
- Cannabinoid 1 and Transient Receptor Potential Vanilloid 1 Receptors Discretely Modulate Evoked Glutamate Separately from Spontaneous Glutamate Transmission
- (2014) J. A. Fawley et al. JOURNAL OF NEUROSCIENCE
- Early phytocannabinoid chemistry to endocannabinoids and beyond
- (2014) Raphael Mechoulam et al. NATURE REVIEWS NEUROSCIENCE
- Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial
- (2014) Michael S. Ritsner et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Cannabis use, gender and age of onset of schizophrenia: Data from the ÆSOP study
- (2014) Kim Donoghue et al. PSYCHIATRY RESEARCH
- Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
- (2014) Christine E. Marx et al. PSYCHOPHARMACOLOGY
- Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia
- (2014) David W. Volk et al. SCHIZOPHRENIA RESEARCH
- Pregnenolone Can Protect the Brain from Cannabis Intoxication
- (2014) Monique Vallée et al. SCIENCE
- Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
- (2013) Celia J. A. Morgan et al. BRITISH JOURNAL OF PSYCHIATRY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
- (2013) Jenny Ceccarini et al. NEUROIMAGE
- Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
- (2013) Felipe V. Gomes et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users
- (2013) M. Di Forti et al. SCHIZOPHRENIA BULLETIN
- Multiple Functions of Endocannabinoid Signaling in the Brain
- (2012) István Katona et al. Annual Review of Neuroscience
- Anandamide Dysfunction in Prodromal and Established Psychosis
- (2012) F. Markus Leweke CURRENT PHARMACEUTICAL DESIGN
- A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
- (2012) Aitor G. Granja et al. Journal of Neuroimmune Pharmacology
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
- (2012) Amir Englund et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
- (2012) Kimberly J. Jenko et al. SCHIZOPHRENIA RESEARCH
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabis Use and Earlier Onset of Psychosis
- (2011) Matthew Large et al. ARCHIVES OF GENERAL PSYCHIATRY
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- (2011) EM Rock et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins TransportN-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid Transport Inhibitors
- (2011) Martin Kaczocha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Grand challenges in global mental health
- (2011) Pamela Y. Collins et al. NATURE
- Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex
- (2011) Victoria S Dalton et al. NEUROPSYCHOPHARMACOLOGY
- Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial
- (2011) Douglas L. Boggs et al. SCHIZOPHRENIA RESEARCH
- Effects of cannabinoids and cannabinoid-enrichedCannabisextracts on TRP channels and endocannabinoid metabolic enzymes
- (2010) Luciano De Petrocellis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Psychosis reactivity to cannabis use in daily life: an experience sampling study
- (2010) Cécile Henquet et al. BRITISH JOURNAL OF PSYCHIATRY
- Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder
- (2010) Michael S. Ritsner et al. JOURNAL OF CLINICAL PSYCHIATRY
- Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia
- (2010) Deanna L. Kelly et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
- (2010) Dean F. Wong et al. NEUROIMAGE
- Disruption of Frontal Theta Coherence by Δ9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms
- (2010) Paul D Morrison et al. NEUROPSYCHOPHARMACOLOGY
- Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder
- (2010) Stephen M Eggan et al. NEUROPSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
- (2009) Paolo Fusar-Poli et al. ARCHIVES OF GENERAL PSYCHIATRY
- Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis
- (2009) Dagmar Koethe et al. BRITISH JOURNAL OF PSYCHIATRY
- High-potency cannabis and the risk of psychosis
- (2009) Marta Di Forti et al. BRITISH JOURNAL OF PSYCHIATRY
- Time-dependent vascular actions of cannabidiol in the rat aorta
- (2009) Saoirse E. O'Sullivan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia
- (2009) Glenn Schwarcz et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
- (2009) Volker Auwärter et al. JOURNAL OF MASS SPECTROMETRY
- Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
- (2009) N. A. Jones et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
- (2009) Christine E Marx et al. NEUROPSYCHOPHARMACOLOGY
- Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo
- (2009) J. Z. Long et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of intracellular carriers for the endocannabinoid anandamide
- (2009) M. Kaczocha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
- (2009) P. D. Morrison et al. PSYCHOLOGICAL MEDICINE
- Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment
- (2009) Leyre Urigüen et al. PSYCHOPHARMACOLOGY
- Weight effects associated with antipsychotics: A comprehensive database analysis
- (2009) Bruce Parsons et al. SCHIZOPHRENIA RESEARCH
- Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia
- (2008) Stephen M. Eggan et al. ARCHIVES OF GENERAL PSYCHIATRY
- Cannabinoid Receptors: Where They are and What They do
- (2008) K. Mackie JOURNAL OF NEUROENDOCRINOLOGY
- Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy
- (2008) Stéphane Potvin et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
- (2008) Jonathan Z Long et al. Nature Chemical Biology
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- (2007) A Thomas et al. BRITISH JOURNAL OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started